Avion Signs an Exclusive License Agreement with ImmuPharma to Develop and Commercialize Lupuzor

Avion Signs an Exclusive License Agreement with ImmuPharma to Develop and Commercialize Lupuzor

Shots:

  • Immuphrama to receive $70M milestones including $5M as regulatory & $65M as commercialization milestones and up to 17% royalties on pre-specified annual US sales targets. ImmuPharma retains all rights to commercialize Lupuzor outside the US and receives an additional $5M on approval of Lupuzor for each additional indication (Ex- Lupus)
  • Avion to get an exclusive right to co-develop Lupuzor and the molecule forigerimod, exclusive right to commercialize Lupuzor in the US. Avion will fund up to $25M in P-III study of Lupuzor with its anticipated onset in 2020, following the agreement of the trial design between Avion, ImmuPharma and the FDA
  • Additionally, the companies signed a trademark license agreement under which Avion has the right to use relevant trademarks for the development, manufacture and commercialization of products

Click here to­ read full press release/ article | Ref: ImmuPharma | Image: ImmuPharma